Serum levels of immunoglobulins and severity of community-acquired pneumonia

BMJ Open Respiratory Research

Volumn 3, Issue 1, 2016, Pages

  de la Torre, Mari C ^a   Torán, Pere ^b   Serra Prat, Mateu ^c   Palomera, Elisabet ^c   Güell, Estel ^a   Vendrell, Ester ^a   Yébenes, Joan Carles ^a   Torres, Antoni ^d   Almirall, Jordi ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Unitat de Suport a la Recerca Metropolitana Nord   (Spain)

^c HOSPITAL DE MATARÓ   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CHRONIC KIDNEY FAILURE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY ASSESSMENT; FEMALE; HOSPITAL CARE; HOSPITALIZATION; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; LUNG INFILTRATE; LUNG PERFUSION; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; NEPHELOMETRY; OBSERVATIONAL STUDY; OUTPATIENT CARE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SEPTIC SHOCK; SMOKING;

EID: 85001907827     PISSN: None     EISSN: 20524439     Source Type: Journal    
DOI: 10.1136/bmjresp-2016-000152     Document Type: Article

References (32)

1. Almirall J, Bolíbar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000;15:757-63.
2. Woodhead MA, Macfarlane JT, McCracken JS, et al. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987;2:671-4.
3. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993;137:977-88.
4. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-72.
5. Marshall JC. Sepsis: current status, future prospects. Curr Opin Crit Care 2004;10:250-64.
6. Meijvis SCA, van de Garde EMW, Rijkers GT, et al. Treatment with anti-inflammatory drugs in community-acquired pneumonia. J Intern Med 2012;272:25-35.
7. Fernandez-Serrano S, Dorca J, Coromines M, et al. Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol 2003;10:813-20.
8. Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010;125:1354-60.
9. Skull S, Kemp A. Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93. Arch Dis Child 1996;74:527-30.
10. de Gracia J, Vendrell M, Alvarez A, et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004;4:745-53.
11. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117(4 Suppl):S525-53.
12. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome—a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999;28:800-7.
13. Hartung HP, Mouthon L, Ahmed R, et al. Clinical applications of intravenous immunoglobulins (IVIg)—beyond immunodeficiencies and neurology. Clin Exp Immunol 2009;158(Suppl 1):23-33.
14. Alfageme I, Aspa J, Bello S, et al., Grupo de Estudio de la Neumonía Adquirida en la Comunidad. Area de Tuberculosis e Infecciones Respiratorias (TIR)-SEPAR. Guidelines for the diagnosis and management of community-acquired pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol 2005;41:279-89.
15. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001;56(Suppl 4):IV1-IV64.
16. Whicher JT, Price CP, Spencer K. Immunonephelometric and immunoturbidimetric assays for proteins. Crit Rev Clin Lab Sci 1983;18:213-60.
17. de la Torre MC, Bolíbar I, Vendrell M, et al. Serum immunoglobulins in the infected and convalescent phases in community-acquired pneumonia. Respir Med 2013;107:2038-45.
18. De Gracia J, Rodrigo MJ, Morell F, et al. IgG subclass deficiencies associated with bronchiectasis. Am J Respir Crit Care Med 1966;153:650-5.
19. Feldman C, Mahomed AG, Mahida P, et al. IgG subclasses in previously healthy adult patients with acute community-acquired pneumonia. S Afr Med J 1996;86:600-2.
20. Herer B, Labrousse F, Mordelet-Dambrine M, et al. Selective IgG subclass deficiencies and antibody responses to pneumococcal capsular polysaccharide antigen in adult community-acquired pneumonia. Am Rev Respir Dis 1990;142:854-7.
21. Gordon CL, Johnson PD, Permezel M, et al. Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency. Clin Infect Dis 2010;50:672-8.
22. Gordon CL, Holmes NE, Grayson ML, et al. Comparison of immunoglobulin G subclass concentrations in severe community-acquired pneumonia and severe pandemic 2009 influenza A (H1N1) infection. Clin Vaccine Immunol 2012;19:446-8.
23. Justel M, Socias L, Almansa R, et al. IgM levels in plasma predict outcome in severe pandemic influenza. J Clin Virol 2013;58:564-7.
24. Hukuhara H, Shigeno Y, Saito A. Serum levels of healthy adult humans and changes of IgG subclass levels between infected and convalescent phase in respiratory infections. Kansenshogaku Zasshi 1991;65:564-70.
25. de la Torre MC, Palomera E, Serra-Prat M, et al. IgG2 as an independent risk factor for mortality in patients with community-acquired pneumonia. J Crit Care 2016;35:115-19.
26. Bermejo-Martín JF, Rodriguez-Fernandez A, Herrán-Monge R, et al. Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis. J Intern Med 2014;276:404-12.
27. Werdan K, Pilz G, Bujdoso O, et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 2007;35:2693-701.
28. Pildal J, Gotzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infec Dis 2004;39:38-46.
29. Kreymann KG, de Heer G, Nierhaus A, et al. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007;35:2677-85.
30. Alejandria MM, Langsang MA, Dans LF, et al. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2002;(1):CD001090.
31. Turgeon AF, Hutton B, Fergusson DA, et al. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007;146:193-203.
32. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007;35:2686-92.